These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26586949)

  • 1. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.
    Frye JW; Peura DA
    Ther Clin Risk Manag; 2015; 11():1649-56. PubMed ID: 26586949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
    Fass R; Frazier R
    Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW; Peura DA
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
    Wittbrodt ET; Baum C; Peura DA
    Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
    Oldfield EC; Parekh PJ; Johnson DA
    Expert Rev Gastroenterol Hepatol; 2016 Oct; 10(10):1083-1089. PubMed ID: 27580358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL
    Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C; Desilets AR; Willett K
    Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
    Mermelstein J; Mermelstein AC; Chait MM
    Clin Exp Gastroenterol; 2016; 9():163-72. PubMed ID: 27471402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
    Goh KL; Choi MG; Hsu PI; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Neurogastroenterol Motil; 2016 Jul; 22(3):355-66. PubMed ID: 26932927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HISTORICAL PERSPECTIVE OF GASTROESOPHAGEAL REFLUX DISEASE CLINICAL TREATMENT.
    Zaterka S; Marion SB; Roveda F; Perrotti MA; Chinzon D
    Arq Gastroenterol; 2019 Aug; 56(2):202-208. PubMed ID: 31460587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexlansoprazole - a new-generation proton pump inhibitor.
    Skrzydło-Radomańska B; Radwan P
    Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
    Ghoshal UC; Blaachandran A; Rai S; Misra A
    Indian J Gastroenterol; 2022 Aug; 41(4):405-414. PubMed ID: 35771390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
    Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.